6533b7dcfe1ef96bd1273406
RESEARCH PRODUCT
Effectiveness of anti-vascular endothelial growth factors in neovascular age-related macular degeneration and variables associated with visual acuity outcomes: Results from the EAGLE study
Giovanni StaurenghiFrancesco BandelloFrancesco ViolaMonica VaranoGiulia BarbatiElena PeruzziStefania BassaniniChiara BiancottoVito FeniciaClaudio FurinoMaria VadalàMichele ReibaldiStela VujosevicFederico RicciEagle Study Investigatorssubject
MaleEaglesAntiVEGF Drugs nAMD clinical practiceVisual AcuitySocial SciencesRetinal NeovascularizationInfographicsGeographical locationsMacular DegenerationMedical ConditionsEndocrinologyRetrospective StudieClinical endpoint80 and overPsychologyAged 80 and overEukaryotaItalyCohortMedicineHumanmedicine.medical_specialtyScienceDrug Administration ScheduleFollow-Up StudieSigns and Symptomsbiology.animalLinear regressionHumansAgedRetrospective StudiesSettore MED/30 - Malattie Apparato VisivoData VisualizationOrganismsBiology and Life Sciencesmedicine.diseaseOphthalmologyMacular DisordersLesionsEyesObservational studyClinical MedicinePeople and placesNeuroscienceVascular Endothelial Growth Factor AVisual acuityTime FactorsEye DiseasesVisionPhysiologyAngiogenesis InhibitorsMedicine and Health SciencesGeriatric OphthalmologyData ManagementMultidisciplinarybiologyQRetinal DegenerationRChartsEuropeAged; Aged 80 and over; Angiogenesis Inhibitors; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Intravitreal Injections; Italy; Macular Degeneration; Male; Retinal Neovascularization; Retrospective Studies; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual AcuityTreatment OutcomeVertebratesIntravitreal InjectionsRetinal DisordersSensory PerceptionFemalemedicine.symptomAnatomyAngiogenesis InhibitorResearch ArticleEagleComputer and Information SciencesTime FactorBirdsOcular SystemInternal medicineSettore MED/30Growth FactorsmedicineAnimalsEuropean UnionRaptorsEndocrine Physiologybusiness.industryIntravitreal InjectionCognitive PsychologyRetrospective cohort studyMacular degenerationGeriatricsAmniotesCognitive SciencePerceptionbusinessZoologyHeadFollow-Up Studiesdescription
Objective To assess the overall effectiveness of anti-vascular endothelial growth factor (VEGF) therapy in treatment-naïve patients with neovascular age-related macular degeneration (nAMD) in a clinical practice setting. Study design EAGLE was a retrospective, 2-year, cohort observational, multicenter study conducted in Italy that analyzed secondary data of treatment-naïve patients with nAMD. The primary endpoint evaluated the mean annualized number of anti-VEGF injections at Years 1 and 2. The main secondary endpoints analyzed the mean change in visual acuity (VA) from baseline and variables associated with visual outcomes at Years 1 and 2. Results Of the 752 patients enrolled, 745 (99.07%) received the first dose of anti-VEGF in 2016. Overall, 429 (57.05%) and 335 (44.5%) patients completed the 1- and 2-year follow-ups, respectively. At baseline, mean (standard deviation, SD) age was 75.6 (8.8) years and the mean (SD) VA was 53.43 (22.8) letters. The mean (SD) number of injections performed over the 2 years was 8.2 (4.1) resulting in a mean (SD) change in VA of 2.45 (19.36) (P = 0.0005) letters at Year 1 and −1.34 (20.85) (P = 0.3984) letters at Year 2. Linear regression models showed that age, baseline VA, number of injections, and early fluid resolution were the variables independently associated with visual outcomes at Years 1 and 2. Conclusions The EAGLE study analyzed the routine clinical practice management of patients with nAMD in Italy. The study suggested that visual outcomes in clinical practice may be improved with earlier diagnosis, higher number of injections, and accurate fluid resolution targeting during treatment induction.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2021-09-01 |